

Molekylärdiagnostiska test för män med ökad sannolikhet för prostatacancer

Bilaga 1 Sökstrategi

PubMed 1950–2010 (november)

Sökstrategi: effekt av molekylärdiagnostiska test samt ekonomiska aspekter

Prostate	AND	Pca3 (TI/AB)
Prostatic neoplasms		Prostate cancer antigen 3 (TI/AB)
Prostate (TI/AB)		Prostate cancer antigen 3, human (SN)
Prostatic (TI/AB)		Dd3 (TI/AB)
		Tmprss2 erg (TI/AB)
		Tmprss2 erg fusion protein, human (SN)
		Transmembrane protease serine 2 (TI/AB)
		Gstp1 (TI/AB)
		Glutathione s transferase pi
		Glutathione s transferase (TI/AB)

Cochrane Library t o m november 2010

Sökstrategi: effekt av molekylärdiagnostiska test samt ekonomiska aspekter

Prostate	AND	Pca3 (ti, ab, kw)
Prostatic neoplasms		Prostate cancer antigen 3 (ti, ab, kw)
Prostate (ti, ab, kw)		Dd3 (ti, ab, kw)
Prostatic (ti, ab, kw)		Tmprss2 erg (ti, ab, kw)
		Transmembrane protease serine 2 (ti, ab, kw)
		Gstp1 (ti, ab, kw)
		Glutathione s transferase pi
		Glutathione s transferase (ti, ab, kw)

Embase 1966–2010 (november)

Sökstrategi: effekt av molekylärdiagnostiska test samt ekonomiska aspekter

Prostate/exp	AND	Pca3 (TW)
Prostate tumor/exp		Prostate cancer antigen 3 (TW)
Prostate (TW)		Dd3 (TW)
Prostatic (TW)		Tmprss2 erg (TW)
		Transmembrane protease serine 2 (TW)
		Gstp1 (TW)
		Glutathione s transferase pi /exp
		Glutathione s transferase pi (TW)

Söktermerna i PubMed har utgjorts av MeSH-termer (NLM:s kontrollerade nyckelord, Medical Subject Heading) om inget annat anges.

TI/AB = title/abstract; **SN** = substance name

Söktermerna i Cochrane Library har utgjorts av MeSH-termer (NLM:s kontrollerade nyckelord, Medical Subject Heading) om inget annat anges.

ti = title; **ab** = abstract; **kw** = keyword

Söktermerna i Embase har utgjorts av nyckelord specifika för databasen.

/exp = explode (map to preferred term); **TW** = text word

Bilaga 2 Exkluderade studier

Uppfyller inte samtliga inklusionskriterier (enligt relevansmall/ PICO) eller dubbelpublikation

Baden J, Green G, Painter J, Curtin K, Markiewicz J, Jones J, et al. Multicenter evaluation of an investigational prostate cancer methylation assay. *J Urol* 2009;182:1186-93.

De Luca S, Randone DF, Bellei L, Vestita E, Volpe A, Terrone C, et al. PCA3 urine assay and diagnosis of prostate cancer on repeat prostate biopsy: Experience on 227 cases. *Anticancer Research*, 30 (2010) 1407-8.

Drewnowska K, Crawford ED, Qian J, Varvel S, Wilk M, Mason L, et al. PCA3: A urine-based genetic assay for detection of prostate cancer in men with elevated PSA. *J Clin Oncol* 27:15s, 2009 (suppl; abstr 5054).

Goessl C, Krause H, Müller M, Heicappell R, Schrader M, Sachsinger J, et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. *Cancer Res* 2000;60:5941-5.

Goessl C, Müller M, Heicappell R, Krause H, Miller K. DNA-based detection of prostate cancer in blood, urine, and ejaculates. *Ann N Y Acad Sci* 2001;945:51-8.

Goessl C, Müller M, Heicappell R, Krause H, Straub B, Schrader M, et al. DNA-based detection of prostate cancer in urine after prostatic massage. *Urology* 2001;58:335-8.

Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. *Clin Cancer Res* 2003;9:2673-7.

Henderson J, Ghani KR, Cook J, Fahey M, Schalken J, Thilagarajah R. The role of PCA3 testing in patients with a raised prostate-specific antigen level after Greenlight photoselective vaporization of the prostate. *J Endourol* 2010;24:1821-4.

Hessels D, van Gils MP, van Hooij O, Jannink SA, Witjes JA, Verhaegh GW, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. *Prostate* 2010;70:10-6.

Jerónimo C, Usadel H, Henrique R, Silva C, Oliveira J, Lopes C, et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. *Urology* 2002;60:1131-5.

Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. *Cancer Res* 2008;68:645-9.

Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. *J Urol* 2008;179:1804-9; discussion 9-10.

Rogers CG, Gonzalgo ML, Yan G, Bastian PJ, Chan DY, Nelson WG, et al. High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection. *J Urol* 2006;176:2280-4.

Roobol MJ, Schröder FH, van Leeuwen P, Wolters T, van den Bergh RC, van Leenders GJ, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. *Eur Urol* 2010;58:475-81.

Rouprêt M, Hupertan V, Yates DR, Catto JW, Rehman I, Meuth M, et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. *Clin Cancer Res* 2007;13:1720-5.

Shen M, Chen W, Yu K, Chen Z, Zhou W, Lin X, et al. The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population. *Exp Mol Pathol* 2011;90:97-100.